ophthalmology

News

Downward market trajectory in black bar chart

Outlook blindsided as FDA blocks wet AMD drug once again

Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.

News

Nicox plans filings for glaucoma after phase 3 win

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.

News

England poised to roll out drug for rare eye disease LHON

Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.

News

FDA fast-tracks Sanofi's gene therapy for eye disease GA

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy, a major cause of blindness.

News

Boehringer raises hope of oral drug for diabetic eye disease

Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

News

After FDA says no, Bayer bags EU nod for twice-yearly Eylea

Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.

Outlook blindsided as FDA blocks wet AMD drug once again

Nicox plans filings for glaucoma after phase 3 win

England poised to roll out drug for rare eye disease LHON

FDA fast-tracks Sanofi's gene therapy for eye disease GA

Boehringer raises hope of oral drug for diabetic eye disease

After FDA says no, Bayer bags EU nod for twice-yearly Eylea

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

ophthalmology

Editor's Picks